1WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO 1972, no498.
2Laurence D, Carpenter J. A dictionary of pharmacology and allied topics, 2nd edn. Amsterdam: Elsevier, 1998: 8-9.
3Stephens MDB. Definitions and classifications of adverse reaction terms. In: Stephens MDB, Talbot JCC, Routledge PA, eds. The detection of new adverse reactions, 4th edn. London: Macmillan Reference, 1998: 32 - 44.
4Ferner RE, Aronson JK. Errors in prescribing,preparing, and giving medicines- definition, classification, and prevention. In: Aronson JK, ed.Side effects of drugs, annual 22. A worldwide yearly survey of new data and trends. Amsterdam:Elsevier, 1999: xxiii - xxxvi.
5Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29 - 34.
6Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1: 39 - 45.
7WHO. International monitoring of adverse reactions to drugs: adverse reaction terminology.WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 1992.
8Wood KL, on behalf of the MEDDRA Working Party. The medical dictionary for drug regulatory affairs (MEDDRA). Pharmacoepidemiol Drug Saf1994; 3: 7- 13.
9Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In; Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 10.
10Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions, 2nd edn. Oxford:Oxford University Press, 1981: 11.
